BRPI0907011A2 - Formulação de liberação sistentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo - Google Patents

Formulação de liberação sistentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo

Info

Publication number: BRPI0907011A2
Authority: BR; Brazil
Prior art keywords: polylactpide; coglycolide; octreotide; polymers; linear
Prior art date: 2008-01-30

Application number

BRPI0907011-7A

Other languages

English (en)

Inventor

Holger Petersen

Markus Ahlheim

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-30

Filing date

2009-01-29

Publication date

2015-07-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39577789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907011(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-29 Application filed by Novartis Ag filed Critical Novartis Ag

2015-07-07 Publication of BRPI0907011A2 publication Critical patent/BRPI0907011A2/pt

2015-09-29 Publication of BRPI0907011A8 publication Critical patent/BRPI0907011A8/pt

Links

DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
108010016076 Octreotide Proteins 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960002700 octreotide Drugs 0.000 title 1
229920000642 polymer Polymers 0.000 title 1
230000009885 systemic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dispersion Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compositions Of Macromolecular Compounds (AREA)
Polyesters Or Polycarbonates (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0907011A 2008-01-30 2009-01-29 formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo BRPI0907011A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08150826		2008-01-30
PCT/EP2009/051026 WO2009095450A1 (en)	2008-01-30	2009-01-29	Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

Publications (2)

Publication Number	Publication Date
BRPI0907011A2 true BRPI0907011A2 (pt)	2015-07-07
BRPI0907011A8 BRPI0907011A8 (pt)	2015-09-29

Family

ID=39577789

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0907011A BRPI0907011A8 (pt)	2008-01-30	2009-01-29	formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo

Country Status (14)

Country	Link
US (2)	US20110003002A1 (pt)
EP (1)	EP2247282B1 (pt)
JP (2)	JP5791278B2 (pt)
KR (2)	KR101921800B1 (pt)
CN (2)	CN101917969A (pt)
AU (1)	AU2009209594A1 (pt)
BR (1)	BRPI0907011A8 (pt)
CA (1)	CA2713339C (pt)
ES (1)	ES2522342T3 (pt)
MX (1)	MX2010008365A (pt)
PL (1)	PL2247282T3 (pt)
PT (1)	PT2247282E (pt)
RU (1)	RU2541104C2 (pt)
WO (1)	WO2009095450A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102526700B (zh) *	2011-12-31	2014-08-06	江苏奥赛康药业股份有限公司	一种注射用醋酸奥曲肽冻干组合物及其制备方法
TWI562991B (en)	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EP2823808A1 (en) *	2013-07-09	2015-01-14	Ipsen Pharma S.A.S.	Pharmaceutical composition for a sustained release of lanreotide
CN106727358A (zh) *	2017-01-24	2017-05-31	广州帝奇医药技术有限公司	阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法
MX2022002980A (es)	2019-09-16	2022-04-06	Amgen Inc	Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
EP4329734A4 (en) *	2021-04-26	2025-04-02	Celanese EVA Performance Polymers LLC	Implantable device for the delayed release of a macromolecular drug compound
TW202308595A (zh) *	2021-08-13	2023-03-01	大陸商江西濟民可信集團有限公司	一種微球懸液、微粒製劑及其製備方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2316052C (en)	1989-07-07	2008-09-02	David Bodmer	Sustained release formulations of water soluble peptides
HU221294B1 (en)	1989-07-07	2002-09-28	Novartis Ag	Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en)	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
PH30995A (en) *	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
AR012448A1 (es) *	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
CN1684663A (zh) *	2002-07-31	2005-10-19	阿尔萨公司	可注射的多模式聚合物储库组合物以及其用途
US7368126B2 (en) *	2002-11-06	2008-05-06	Guohua Chen	Controlled release depot formulations
KR100466637B1 (ko) *	2003-06-26	2005-01-13	주식회사 펩트론	서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
AU2004259209A1 (en)	2003-07-23	2005-02-03	Pr Pharmaceuticals, Inc.	Controlled release compositions
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
KR20130024988A (ko) *	2005-12-22	2013-03-08	노파르티스 아게	옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제

2009
- 2009-01-29 CA CA2713339A patent/CA2713339C/en not_active Expired - Fee Related
- 2009-01-29 KR KR1020167010517A patent/KR101921800B1/ko active Active
- 2009-01-29 RU RU2010135629/15A patent/RU2541104C2/ru active
- 2009-01-29 AU AU2009209594A patent/AU2009209594A1/en not_active Abandoned
- 2009-01-29 PT PT97054548T patent/PT2247282E/pt unknown
- 2009-01-29 WO PCT/EP2009/051026 patent/WO2009095450A1/en not_active Ceased
- 2009-01-29 CN CN2009801025770A patent/CN101917969A/zh active Pending
- 2009-01-29 CN CN201410317482.3A patent/CN104127367A/zh active Pending
- 2009-01-29 MX MX2010008365A patent/MX2010008365A/es active IP Right Grant
- 2009-01-29 PL PL09705454T patent/PL2247282T3/pl unknown
- 2009-01-29 KR KR1020107017006A patent/KR20100110848A/ko not_active Ceased
- 2009-01-29 EP EP09705454.8A patent/EP2247282B1/en active Active
- 2009-01-29 JP JP2010544702A patent/JP5791278B2/ja active Active
- 2009-01-29 ES ES09705454.8T patent/ES2522342T3/es active Active
- 2009-01-29 BR BRPI0907011A patent/BRPI0907011A8/pt active Search and Examination
- 2009-01-29 US US12/865,145 patent/US20110003002A1/en not_active Abandoned
2012
- 2012-05-15 US US13/472,219 patent/US8999390B2/en active Active
2014
- 2014-12-26 JP JP2014265878A patent/JP2015107985A/ja active Pending

Also Published As

Publication number	Publication date
CN104127367A (zh)	2014-11-05
KR20160052756A (ko)	2016-05-12
EP2247282B1 (en)	2014-08-20
CN101917969A (zh)	2010-12-15
JP5791278B2 (ja)	2015-10-07
KR101921800B1 (ko)	2018-11-23
CA2713339C (en)	2017-01-17
JP2015107985A (ja)	2015-06-11
US20120226224A1 (en)	2012-09-06
BRPI0907011A8 (pt)	2015-09-29
MX2010008365A (es)	2010-08-23
KR20100110848A (ko)	2010-10-13
CA2713339A1 (en)	2009-08-06
PT2247282E (pt)	2014-11-11
US20110003002A1 (en)	2011-01-06
RU2541104C2 (ru)	2015-02-10
PL2247282T3 (pl)	2015-03-31
WO2009095450A1 (en)	2009-08-06
ES2522342T3 (es)	2014-11-14
AU2009209594A1 (en)	2009-08-06
JP2011510951A (ja)	2011-04-07
EP2247282A1 (en)	2010-11-10
US8999390B2 (en)	2015-04-07
RU2010135629A (ru)	2012-03-10

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-11-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-03-19	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-07-09	B11D	Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time

Publication	Publication Date	Title
BRPI0908596A2 (pt)	2015-09-15	formulação e composição farmacêutica de liberação prolongada
BRPI0914630A2 (pt)	2019-09-24	liberação dérmica
BRPI0918734A2 (pt)	2015-12-01	material polimérico
BRPI0917358A2 (pt)	2015-11-17	formulação farmacêutica de liberação controlada e método.
BRPI0918652A2 (pt)	2015-08-25	Composições farmacêuticas e métodos de libração relacionadas.
DE112009000905A5 (de)	2011-01-20	Implantierbare Nanopartikel-enthaltende Produkte
BRPI0909780A2 (pt)	2015-08-11	Composições e métodos para liberação de fármaco
BRPI0922989A2 (pt)	2015-08-11	Liberação sustentada de nutrientes in vivo
EP2352781A4 (en)	2013-03-13	BIODEGRADABLE POLYMERIC COMPOSITION
EP2299953A4 (en)	2013-05-29	MEDICAMENT COMPOSITION WITH DELAYED RELEASE
ATE488227T1 (de)	2010-12-15	Feste zubereitung mit alogliptin und pioglitazon
EP2341905A4 (en)	2013-10-23	FORMULATIONS WITH NON-AQUEOUS SUPPORTS AND DELAYED FRUIT
BRPI0721969A2 (pt)	2015-09-29	regime de dosagem de ibuprofeno de liberação imediata e de liberação sustentada
EP2373844A4 (en)	2013-09-04	ACTIVE POLYMER FILMS
NO20081244L (no)	2009-09-11	Ryggestotteanordning
EP2274043A4 (en)	2013-07-31	BIODEGRADABLE METAL-CHELATING POLYMERS AND VACCINES
EP2496267A4 (en)	2016-02-17	ZWITTERIONIC POLYMER BIOKON JUGATES AND CORRESPONDING METHODS
BRPI0907747A2 (pt)	2015-07-21	Dispositivo de lingueta
SE0801651L (sv)	2010-01-10	Granuleringskvarn
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
BRPI0922423A2 (pt)	2015-12-15	dispositivo de liberação de fármaco
FR2933299B1 (fr)	2012-02-03	Mannitol orodispersible
BRPI0907855A2 (pt)	2015-07-21	Dispositivo para plastilhamento
BRPI0907011A8 (pt)	2015-09-29	formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo
BRPI0811732A2 (pt)	2014-11-18	Formulação de liberação prolongada de nevirapina